Switzerland boasts highest number of FemTech longevity companies in continental Europe
Switzerland hosts half of continental Europe’s FemTech longevity companies. The country also ranks third globally for number of FemTech accelerator programs
With 13% of the global market share, Switzerland ranks second for the number of FemTech longevity companies, after the US (58%) and before the UK (6%). FemTech longevity companies are developing technologies to improve women’s health and lifespan.
Switzerland is also the third country in the world for the number of FemTech community organisations with 14% of the global share, after the USA (32%) and the UK (23%). Community organisations include global networks and accelerator programs that help FemTech businesses grow. These include Tech4Eva, the first FemTech accelerator program in continental Europe, run by EPFL Innovation Park and sponsored by Groupe Mutuel.
Switzerland ranks fourth globally with $398 million invested in FemTech. The US leads with over $10 billion, followed by Israel with $1.25 billion and the UK with $611 million.
Kate Batz, director of FemTech Analytics commented: “The rapid rise of startups dedicated to women’s health in Switzerland has been phenomenal. FemTech is increasingly becoming a prosperous sector and a promising asset class for investors. With over 30 FemTech companies and prominent investment companies in the market, Switzerland represents a great opportunity for FemTech founders and investors”.
Wearables, mobile applications and home testing devices are driving the development of FemTech in Switzerland, where the market comprises 85 FemTech organisations, of which 33 are companies, 15 are NGOs and 37 are investors. Over 50% of Swiss FemTech companies operate in reproductive health & contraception, and pregnancy & nursing; and 88% are based in Northern and Western Switzerland. Zurich leads with 14 FemTech companies, followed by Vaud (8), Basel-Stadt (4), Geneve (3) and Bern (2).
Globally, the US continues to lead the FemTech market with the highest number of companies (51%), followed by the UK and Israel in their regions with 10% and 6% respectively. India is Asia's market leader with 4% of companies.
The report is based on the analysis of over 1,300 FemTech companies, 1,290 investors, 14 R&D centres and 22 community organisations. It showcases market trends, innovations, growth opportunities and investment prospects. It also includes interviews with FemTech leaders like Oriana Kraft (Producer of FemTech Summit - ETH Zurich) and Ksenia Tugay (Strategic Innovation Expert at Groupe Mutuel), case studies of prominent FemTech companies and the list of the top 150 FemTech influencers.
The report reveals a growing interest of VCs and angel investors in FemTech and an increasing demand for reproductive health products and services. Nonetheless, the level of investments in FemTech remains low as highlighted by the 2021 Global FemTech Survey published in October 2021.
Additional findings:
- 85% of all FemTech companies generate annual revenues of less than $10 million each
- FemTech companies that raised the highest amount of investment are Evofem ($444.2 million in Post-IPO Equity), Progenity ($248.5 million in Post-IPO Equity), Agile Therapeutics ($204.5 million in Post-IPO Equity), Elvie ($151.9 million in Series C) and The Mom Project ($115 million in Series C)
- More than 50% of FemTech companies operate in the areas of pregnancy and nursing, reproductive health and contraception and general healthcare. Companies providing pregnancy and nursing solutions such as Baymatob and Expectful make 21% of the market, the ones operating in reproductive health and contraception like Carrot and Phexxi and general healthcare like Syantra and Tia account respectively for 17% and 14%
- Other FemTech sub sectors include Women's Wellness, Menstrual Health, Mental Health, Pelvic and Uterine Healthcare
- Menstrual health products are among the most popular. These include reusable absorbent sanitary items, reusable cups and flushable pads providing a safe, convenient, affordable and environmentally friendly option
- FemTech diagnostic solutions are dominant in general healthcare (31%), apps and software are popular in the FemTech longevity sector (32%).
--- END ---
Notes to editor
Links to the reports mentioned in the press release
2021 Global FemTech report
https://www.femtech.health/femtech-overview-q4-2021
2021 Global Mindmap
https://mindmaps.femtech.health/global-femtech-ecosystem-q4-2021
2021 Swiss FemTech report
https://www.femtech.health/femtech-switzerland
2021 Swiss Mindmap
https://mindmaps.femtech.health/femtech-industry-switzerland
2021 Global FemTech Survey
https://www.femtech.health/femtech-overview-q4-2021
About FemTech Analytics
FemTech Analytics (FTA) is a strategic analytical agency focused on the emerging FemTech sector, providing insights into key sub-sectors such as Reproductive Health & Contraception, General Healthcare, Longevity, Mental Health, Menstrual Health, Pregnancy & Nursing, Sexual Health, Pelvic & Uterine Healthcare, Menopause Care, and Women's Wellness. FTA offers a range of services including research and in-depth analysis on the FemTech industry, profiling companies and government agencies based on their innovation potential and business activity, and consulting and analytical services to advance the overall FemTech sector.
FemTech Analytics is part of Deep Knowledge Group, a consortium of commercial and nonprofit organisations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, media, philanthropy, and more.
FemTech Analytics www.femtech.health
Email: info@femtech.health
Roberto Napolitano
Deep Knowledge Group
+44 7706 138432
rn@dkv.global
Visit us on social media:
Facebook
Twitter
LinkedIn
Other
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![](https://www.einnews.com/tracking/article.gif?aid=558340504§ion=einpresswire&a=QkjqulQJTd40vgDZ&i=AdOrRZ4EG_akmHTc)